DalsnaFinance Account

Ptc Therapeutics Inc $PTCT

Health Care

Russell 2000 New Jersey

Create a scorecard

$62.96

+0.34 (+0.54%)

As of Oct 22, 2026, 3:57 PM EDT · cached

Price history

Loading chart…

Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 7, 2026, the first target we tracked for PTCT.

Ptc Therapeutics Inc (PTCT) is trading up at $62.96 (+0.54%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

Analyst price targets on PTCT

One firm's current price target on Ptc Therapeutics Inc: $85 — 35% above the current $63. Each is tracked to its date and scored the same way a member's call is.

RBC Capital Markets $63.7 → $85 by Oct 2027 Sector Perform Oct 7, 2026 via Investing.com · RBC Capital Markets's track record

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Ptc Therapeutics Inc revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)

Ptc Therapeutics Inc annual financial statements
	FY2016Dec 2016	FY2017Dec 2017	FY2018Dec 2018	FY2019Dec 2019	FY2020Dec 2020	FY2021Dec 2021	FY2022Dec 2022	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$82.7M	$194.4M	$264.7M	$307.0M	$380.8M	$538.6M	$698.8M	$937.8M	$806.8M	$1.73B
Growth (year over year)	+124.9%	+135.0%	+36.2%	+16.0%	+24.0%	+41.4%	+29.7%	+34.2%	−14.0%	+114.5%
Gross profit	$82.7M	$189.8M	$252.1M	$294.8M	—	—	—	—	—	—
Gross margin	100.0%	97.6%	95.2%	96.0%	—	—	—	—	—	—
Operating income	−$132.1M	−$64.3M	−$115.7M	−$241.2M	−$431.8M	−$374.4M	−$447.4M	−$439.5M	−$302.6M	$866.9M
Operating margin	−159.7%	−33.1%	−43.7%	−78.6%	−113.4%	−69.5%	−64.0%	−46.9%	−37.5%	50.1%
Net income	−$142.1M	−$79.0M	−$128.1M	−$251.6M	−$438.2M	−$523.9M	−$559.0M	−$626.6M	−$363.3M	$682.6M
Net margin	−171.8%	−40.6%	−48.4%	−82.0%	−115.1%	−97.3%	−80.0%	−66.8%	−45.0%	39.4%
EPS (diluted)	−$4.17	−$2.02	−$2.75	−$4.27	−$6.64	−$7.43	−$7.79	−$8.37	−$4.73	$7.78
Balance sheet
Cash and equivalents	$58.3M	$111.8M	$169.5M	$288.0M	$208.8M	$189.7M	$279.8M	$594.0M	$779.7M	$984.6M
Total assets	$269.3M	$391.7M	$1.12B	$1.62B	$2.21B	$1.94B	$1.71B	$1.90B	$1.71B	$2.90B
Total liabilities	$149.8M	$235.2M	$768.5M	$1.03B	$1.73B	$1.94B	$2.05B	$2.71B	$2.80B	$3.10B
Long-term debt	$98.2M	$145.0M	$141.3M	$293.9M	$309.1M	$281.9M	$571.7M	$284.2M	$285.4M	—
Shareholders' equity	$119.6M	$156.4M	$350.7M	$594.3M	$482.0M	$1.44M	−$347.1M	−$818.6M	−$1.10B	−$205.3M
Cash flow
Operating cash flow	−$103.6M	−$10.1M	−$27.6M	−$98.6M	−$194.1M	−$251.3M	−$356.7M	−$158.4M	−$107.7M	$711.2M
Capital expenditure	$1.78M	$3.10M	$7.10M	$13.8M	$17.8M	$28.2M	$32.0M	$28.4M	$6.50M	$8.86M
Free cash flow	−$105.3M	−$13.2M	−$34.7M	−$112.4M	−$211.9M	−$279.5M	−$388.7M	−$186.9M	−$114.2M	$702.3M

RevenueNet incomeNet margin (right axis, %)

Ptc Therapeutics Inc quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$196.8M	$213.2M	$1.18B	$178.9M	$211.0M	$164.7M	$272.6M	$360.5M
Growth (year over year)	+0.1%	−30.6%	+459.7%	−4.2%	+7.2%	−22.7%	−76.8%	+101.5%
Operating income	−$54.5M	−$162.4M	$970.2M	−$35.0M	$3.02M	−$71.3M	$45.0M	$149.0M
Operating margin	−27.7%	−76.2%	82.5%	−19.5%	1.4%	−43.3%	16.5%	41.3%
Net income	−$106.7M	−$65.9M	$866.6M	−$64.8M	$15.9M	−$135.0M	−$2.81M	$83.5M
Net margin	−54.2%	−30.9%	73.7%	−36.3%	7.5%	−82.0%	−1.0%	23.2%
EPS (diluted)	−$1.39	−$0.85	$10.04	−$0.83	$0.20	−$1.63	−$0.03	$0.92
Balance sheet
Cash and equivalents	$526.0M	$779.7M	$1.48B	$1.02B	$672.6M	$984.6M	$834.0M	$1.05B
Total assets	$1.84B	$1.71B	$2.66B	$2.63B	$2.64B	$2.90B	$2.87B	$3.25B
Total liabilities	$2.90B	$2.80B	$2.84B	$2.84B	$2.80B	$3.10B	$3.05B	$3.42B
Long-term debt	$285.1M	$285.4M	$285.7M	$286.0M	—	—	—	$535.5M
Shareholders' equity	−$1.05B	−$1.10B	−$185.8M	−$206.5M	−$155.8M	−$205.3M	−$180.5M	−$165.4M
Cash flow
Operating cash flow	−$77.0M	−$30.0M	$870.1M	−$58.3M	−$66.3M	−$34.3M	−$59.0M	$129.1M
Capital expenditure	$522.0K	$3.77M	$1.72M	$1.25M	$3.52M	$2.37M	$1.20M	$2.19M
Free cash flow	−$77.5M	−$33.8M	$868.4M	−$59.6M	−$69.8M	−$36.6M	−$60.2M	$126.9M

From Ptc Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →